Syndax Pharmaceuticals Garners $80,000,000 New Financing

  • Feed Type
  • Date
    8/24/2015
  • Company Name
    Syndax Pharmaceuticals
  • Mailing Address
    400 Totten Pond Road Waltham, MA 02451 USA
  • Company Description
    Syndax Pharmaceuticals, Inc. is a Waltham, MA-based, oncology-focused biotechnology company that is building a portfolio of new oncology products to extend and improve the lives of patients by developing and commercializing novel cancer therapies in optimized, mechanistically driven combination regimens.
  • Website
    http://www.syndax.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $80,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    This new C round may well signal that a new attempt to go public is in the offing, with its lead drug–which was awarded a breakthrough drug designation by the FDA–in Phase III for breast cancer.
  • M&A Terms
  • Venture Investor
    Fidelity Management & Research Company
  • Venture Investor
    Delos Capital
  • Venture Investor
    EcoR1 Capital Management
  • Venture Investor
    OrbiMed
  • Venture Investor
    Jennison Associates
  • Venture Investor
    Tavistock Life Sciences
  • Venture Investor
    Arrowpoint Partners
  • Venture Investor
    Cormorant Asset Management
  • Venture Investor
    BioMed Ventures
  • Venture Investor
    Domain Associates
  • Venture Investor
    MPM Capital
  • Venture Investor
    RusnanoMedInvest
  • Venture Investor
    Forward Ventures

Trending on Xconomy